GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CABALETTA BIO INC

Explicit Guidance:

• BLA Submission Timeline: The company has updated its guidance to submit the New Drug Application (BLA) for the myositis indication in the first quarter of 2028.
• Cash Runway: With reported cash of $300 million, the company expects its financial runway to extend into the first quarter of 2028, aligning with the projected BLA submission date.
• Data Submission Plan: The company plans to include Phase 1/2 one-year data (presented at ACR) within the BLA submission to demonstrate durability of response following a single dose, leveraging existing 2–3 years of patient follow-up data available at the time of submission.

Business-Segment Outlook:

• Myositis (Adult & Juvenile): The Phase 3 pivotal enrollment is accelerating after a summer slowdown caused by competitor safety events; the company anticipates data reflecting deepening responses over time. The inclusion of juvenile myositis data in the BLA is strategically critical to potentially qualify for a Priority Review Voucher (PRV), which could be monetized to fund future operations.
• Systemic Sclerosis (SSc): The registrational program has initiated with a focus on patients with interstitial lung disease (ILD). The primary endpoint is the change in percent predicted Forced Vital Capacity (FVC). The company anticipates a significant market opportunity given the severity of the disease and observed 9% average FVC improvement at one year.
• Lupus Nephritis: The company is currently evaluating a preconditioning-free (PC-free) approach. A go-forward direction regarding indications and the PC-free program plan is expected to be disclosed in the first half of next year following the collection of substantive data.
• Pemphigus & Myasthenia Gravis: These indications are currently evaluating various doses of the PC-free regimen alongside the lupus program to gather a substantive dataset on patient numbers and follow-up duration.
• Commercial Launch Strategy: Commercial preparation involves a phased approach targeting three cohorts: Adult Dermatomyositis (DM), Juvenile DM, and Systemic Sclerosis. Site selection is being optimized for a commutable radius to highly mobile patient populations, with initial sizing calibrated to accommodate the eventual SSc launch, which is not considered a "distant future" event.

Market and Competitive Outlook:

• Class Maturation: Management views the current period as a transition for the CAR-T class from "novel modality" to a "real class of drugs" for rheumatology, driven by emerging efficacy and safety data.
• Safety Differentiation: Following recent adverse safety events with competitor cell therapies (Bristol, Novartis), the company expects the market to reassess the sector. Carpaletta differentiates itself through a low frequency of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and zero observed ICHS across 70 treated patients.
• Outpatient Adoption: The company anticipates a rapid trajectory toward outpatient administration. Clinical trial data indicates a quicker adoption rate in outpatient settings compared to prior CAR-T experiences (e.g., Carvicti), supported by the healthy T-cell viability of autoimmune patients (vs. cancer patients) leading to higher manufacturing success rates.
• Payer Perspective: Payers and insurers are shifting focus from conceptual TPPs (Target Product Profiles) to real-world proof of durability beyond one year and deep responses, which the company now demonstrates. The long-term value proposition for the juvenile population is highlighted as a substantial monetization opportunity.

Macro / Industry Outlook:

• Competitive Landscape: While competitor safety setbacks caused temporary enrollment slowdowns in the broader cell therapy sector, the company expects these events to validate the importance of rigorous safety profiles, benefiting well-characterized programs like Rezacel.
• Regulatory Environment: The FDA has engaged in interactions supporting the inclusion of long-term durability data in the BLA. The potential for a Priority Review Voucher via the juvenile myositis indication represents a specific regulatory lever to accelerate review and generate capital.
• Manufacturing Environment: The autoimmune patient population is expected to yield significantly better manufacturing success rates and lower out-of-spec rates compared to oncology, reducing operational friction.

Strategic Initiatives:

• PC-Free Regimen Expansion: Actively evaluating preconditioning-free dosing across three indications (Pemphigus, Lupus, Myasthenia Gravis) to simplify treatment and potentially expand addressable markets.
• Site Certification & Network: Strategic selection and certification of clinical sites to ensure they are within a commutable radius for the patient population, balancing immediate adult DM launch needs with future SSc launch capacity.
• Translational Research: Leveraging detailed cytokine data and PK/PD modeling to understand the mechanism of safety and efficacy, informing future development choices across disease indications.

Risks and Headwinds to Outlook:

• Clinical Trial Execution: Reliance on the Phase 3 pivotal study delivering results consistent with Phase 1/2 durability and efficacy; any deviation could impact the BLA filing timeline.
• Market Perception & Safety Events: Continued negative sentiment in the broader CAR-T space due to competitor adverse events could delay provider willingness to adopt the therapy, despite specific safety data.
• Regulatory Uncertainty: While aiming for a Priority Review Voucher, the final determination of inclusion in the label and the monetization value of such a voucher remain subject to regulatory approval and market dynamics.
• Enrollment Dependencies: Previous enrollment slowdowns were linked to external safety events; future delays could occur if the investigator community remains cautious or if patient screening pipelines do not maintain the current uptick.

Management Tone on the Future:

• High Confidence: Management expresses strong confidence that the "vision" for Rezacel has come to reality, citing the convergence of safety, efficacy, and durability data.
• Catalyst-Oriented: There is a clear focus on the immediate "busy" 12-month period, viewing the BLA submission and pivotal data readouts as critical near-term catalysts.
• Strategic Prudence: While optimistic, management emphasizes careful, guided execution regarding outpatient rollout and commercial site sizing, noting a deliberate approach to "not push too hard" on adoption to ensure safety is maintained.

Miscellaneous:

• Value Proposition: The ability for patients to discontinue immunomodulators and often steroids after a single infusion is a key differentiator cited as "not seen in the community" by standard of care.
• Financial Position: The $300M cash position is explicitly framed as sufficient to bridge the company to the strategic milestones of 2028, mitigating immediate funding dilution risks.